Covidien has announced plans for the global launch of its new TurboHawk Plaque Excision System for minimally invasive treatment of peripheral artery disease (PAD). The TurboHawk, which received FDA 510(k) clearance this past January, uses special cutting blades to shave away plaque from obstructed arteries.
From the press release:
PAD is one of the most common vascular diseases and occurs when leg arteries become narrowed or blocked by plaque. These blockages can result in severe pain for patients, limited physical mobility, and non-healing leg ulcers. According to the American Heart Association, approximately eight to 12 million people in the U.S. suffer from PAD.
The innovative design of the TurboHawk device allows for greater cutting efficiency, providing physicians access to a device with more consistent performance. For patients, the minimally invasive nature of the procedure may lead to faster recovery and shorter hospital visits.
Press release: Covidien to Launch TurboHawk™ Plaque Excision System for Small Vessels…
Product page: TurboHawk™ Plaque Excision System…